This suggests that chemical SHIP2 inhibition would be a worthwhile addition to the standard chemotherapy regimen, requiring lower concentrations of chemotherapeutics to achieve the same amount of tumor cell killing. The gene discussed is INPPL1; the disease is neoplasm.